Civitas considers options as inhaled levodopa curtails dyskinesia
This article was originally published in Scrip
Executive Summary
Civitas Therapeutics is mulling its Phase III clinical trial design and financing options based on the success of a Phase IIb trial that showed the company's inhaled levodopa, CVT-301, provided rapid onset and relief from dyskinesia in patients with Parkinson's disease.